The huge load of data for immunotherapies in first-line non-small cell lung cancer presented at the recent American Society of Clinical Oncology meeting left specialists with the task of refining their treatment strategies and sorting out which immunotherapies to use when, in which patients.
Based on data presented at ASCO, held June 1-5 in Chicago, Morningstar Research increased its immuno-oncology (IO) projections overall by 10%, with the change largely coming from non-small cell lung cancer (NSCLC) sales based on strong data from Merck & Co. Inc. and Roche, analyst Damien Conover explained to Scrip
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?